Cart
sales@molnova.com
Upifitamab
CAS No. 2254118-43-7
Upifitamab( —— )
Catalog No. M37099 CAS No. 2254118-43-7
Upifitamab is a naked antibody to upifitamab rilsodotin, which can be used to synthesize the antibody-coupled active molecule UPRI, which can be used to study cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 796 | In Stock |
|
| 10MG | 1036 | In Stock |
|
| 25MG | 1321 | In Stock |
|
| 50MG | 1748 | In Stock |
|
| 100MG | 2353 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameUpifitamab
-
NoteResearch use only, not for human use.
-
Brief DescriptionUpifitamab is a naked antibody to upifitamab rilsodotin, which can be used to synthesize the antibody-coupled active molecule UPRI, which can be used to study cancer.
-
DescriptionUpifitamab is an ADC Antibody (a naked antibody of upifitamab rilsodotin), which can be used for antibody-coupled agent (ADC) synthesis. Upifitamab rilsodotin is an ADC targeting NaPi2b and is used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorADC Antibody
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2254118-43-7
-
Formula WeightApproximately 144.74 kDa.
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Richardson D, et al. Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer (076). Gynecologic Oncology, 2022, 166: S48.
molnova catalog
related products
-
Ethyl 2-ethylhexanoa...
Ethyl 2-ethylhexanoate is a RIFM fragrance and an active ingredient in mosquito repellents.
-
[Ala286]-Calmodulin-...
[Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) is a modified fragment of calcium/calmodulin-dependent protein kinase II that contains the active domain of CaMKII and has an alanine substitution at position 286. [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) can be used to develop more potent CaMKII inhibitors.
-
2,3-Dehydrosilychris...
2,3-Dehydrosilychristin might have a biologically relevant inhibitory effect on ADH and glutamate dehydrogenase.
